ACI’s FCPA & Anti-Corruption for the Life Sciences Industry

Please join Orrick at ACI’s FCPA & Anti-Corruption for the Life Sciences Industry conference on June 19-20 at the Park Lane Hotel in New York, NY where partner Anne Murray will be speaking.

With a number of recent, big ticket enforcement actions against life sciences companies and individuals, the industry continues to combat unique, growing risk factors and government expectations for effective global compliance. As of late, there has been much speculation of a life sciences “industry sweep” by U.S. and international authorities – with new multi-jurisdictional enforcement risks facing life sciences companies and individuals, comes new and evolving compliance expectations.

Anne will be speaking on the panel, “The Heightened Focus on Individual Liability: New, Special Considerations for Pharmaceutical and Medical Device Companies.”

This panel discussion will focus on:

• Recent enforcement actions against individual executives and key takeaways
• Scope of legal and compliance professionals’ obligations to monitor suspicious activity and investigate potential red flags
• What is expected from in-house counsel and compliance executives if your company is under investigation
• Approaches to compliance and legal roles amid developments in the US and globally, and in response to internal corporate and industry pressures
• Examination of high risk regions (China, Mexico, Brazil) and the heightened risks confronting local in-house legal and compliance employees